✦ LIBER ✦

Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study

✍ Scribed by Alice B. Gottlieb; Mark Lebwohl; Sophie Shirin; Amelia Sherr; Pat Gilleaudeau; Giselle Singer; Galina Solodkina; Rachel Grossman; Elvira Gisoldi d; Steven Phillips; H.Mike Neisler; James G. Krueger

Book ID: 117844625
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 577 KB
Volume: 43
Category: Article
ISSN: 1097-6787
DOI: 10.1067/mjd.2000.107945

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multiple dose randomized double-blind

A multiple dose randomized double-blind placebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris

✍ Gottlieb, AB; Krueger, J; Lebwohl, M; Gisoldi, E; Grossman, RM; Wacholtz, MC 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Pharmacodynamic and pharmacokinetic resp

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

✍ Alice B. Gottlieb; Salman Masuda; Rallapalli Ramamurthi; Ahsan Abdulghani; Pat R 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 255 KB

Clinical and histologic response to sing

Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody

✍ Alice B. Gottlieb; Mark Lebwohl; Mark C. Totoritis; Ahsan A. Abdulghani; Steve R 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 299 KB

Efficacy and safety of itolizumab, a nov

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

✍ Krupashankar, D.S.; Dogra, Sunil; Kura, Mahendra; Saraswat, Abir; Budamakuntla, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 694 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

Secukinumab, a human anti-IL-17A monoclo

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

✍ Hueber, W.; Sands, B. E.; Lewitzky, S.; Vandemeulebroecke, M.; Reinisch, W.; Hig 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 304 KB